Company profile
OXOLIFE
Enhancing embryo implantation. Improving women’s fertility
- Industry
- Biotechnology
- Employees
- 5
- Headquarters
- Barcelona, Barcelona
- Founded
- 2013
- LinkedIn followers
- 3,782
- Office locations
- 1
OXOLIFE company summary
OXOLIFE is a company in the Biotechnology industry, headquartered in Barcelona, Barcelona, founded in 2013. On LinkedIn the company has around 5 employees and 3,782 followers. Its listed specialties include R&D, fertility, Human reproduction, Biotechnology, Healthcare.
What technology does OXOLIFE use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About OXOLIFE
Oxolife is a biotechnology company dedicated to enhancing female fertility, with a focus on embryo implantation in women undergoing assisted reproductive technologies (ART). We are developing OXO-001, a first-in-class, non-hormonal oral treatment that directly targets the endometrium, enhancing embryo implantation and increasing Live Birth Rates (LBR). This innovative approach addresses an unmet medical need, as no drug currently exists to specifically increase embryo implantation rates, accounting for 65% Embryo Transfer failures. OXO-001 stands out due to its unique mechanism of action, offering a groundbreaking solution in the fertility space. Following the completion of our Phase II clinical trial, the results have been highly promising, demonstrating a strong balance of efficacy and safety, increasing LBR by 6.9%. These findings position Oxolife to move confidently toward the final stages of clinical development to bring this essential treatment to market, backed by a portfolio of global patents. In addition to our work with OXO-001, we are conducting research aimed at restoring fertility in women affected by polycystic ovarian syndrome (PCOS), a common cause of infertility. Our vision is to improve the chances of live birth for women with infertility, significantly reducing the stress and financial burden associated with infertility treatments for women and couples worlwide. Oxolife is led by Agnès Arbat, MD (Co-founder and CEO), and Ignasi Canals, PhD in Biochemistry (Co-founder and CSO). Together with Oxolife a multidisciplinary, diverse, and high-skilled team, supported by an exceptional international Advisory Board, that has built a robust network of partnerships with key fertility clinics and research institutions, we bring extensive experience in women’s health, pharmaceutical innovation, and drug development.
Specialties
Where is OXOLIFE located?
OXOLIFE lists 1 location.
Compare companies similar to OXOLIFE
More companies in Biotechnology.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
OXOLIFE oxolife.com | Biotechnology | 5 | 2013 | Barcelona, Barcelona |
 Regeneron regeneron.com | Biotechnology | 17,234 | - | Tarrytown, New York |
 Bharat Biotech bharatbiotech.com | Biotechnology | 2,035 | 1996 | Hyderabad, Telangana |
 Enzene Biosciences Ltd enzene.com | Biotechnology | 1,023 | 2008 | Pune, Maharashtra |
| Biotechnology | 393 | - | Bethesda, MD | |
 LifeCell International Pvt.Ltd lifecell.in | Biotechnology | 2,650 | 2004 | Chennai, India |
 TMG - Tropical Melhoramento & Genética tmg.agr.br | Biotechnology | 692 | 2001 | Cambé, PR |
 Organica Biotech organicabiotech.com | Biotechnology | 146 | 2000 | Mumbai, Maharashtra |
 Allogene Therapeutics allogene.com | Biotechnology | 217 | 2017 | South San Francisco, California |
 Labtest Diagnóstica S.A. labtest.com.br | Biotechnology | 227 | 1971 | Lagoa Santa, Minas Gerais |
 Orchard Therapeutics - U.S. orchard-tx.com | Biotechnology | 243 | 2015 | London, United Kingdom |
Frequently asked questions about OXOLIFE
What does OXOLIFE do?
Oxolife is a biotechnology company dedicated to enhancing female fertility, with a focus on embryo implantation in women undergoing assisted reproductive technologies (ART). We are developing OXO-001, a first-in-class, non-hormonal oral treatment that directly targets the endometrium, enhancing embryo implantation and increasing Live Birth Rates (LBR). This innovative approach addresses an unmet medical need, as no drug currently exists to specifically increase embryo implantation rates, accounting for 65% Embryo Transfer failures. OXO-001 stands out due to its unique mechanism of action, offering a groundbreaking solution in the fertility space. Following the completion of our Phase II clinical trial, the results have been highly promising, demonstrating a strong balance of efficacy and safety, increasing LBR by 6.9%. These findings position Oxolife to move confidently toward the final stages of clinical development to bring this essential treatment to market, backed by a portfolio of global patents. In addition to our work with OXO-001, we are conducting research aimed at restoring fertility in women affected by polycystic ovarian syndrome (PCOS), a common cause of infertility. Our vision is to improve the chances of live birth for women with infertility, significantly reducing the stress and financial burden associated with infertility treatments for women and couples worlwide. Oxolife is led by Agnès Arbat, MD (Co-founder and CEO), and Ignasi Canals, PhD in Biochemistry (Co-founder and CSO). Together with Oxolife a multidisciplinary, diverse, and high-skilled team, supported by an exceptional international Advisory Board, that has built a robust network of partnerships with key fertility clinics and research institutions, we bring extensive experience in women’s health, pharmaceutical innovation, and drug development.
How many employees does OXOLIFE have?
OXOLIFE has around 5 employees on LinkedIn.
Where is OXOLIFE headquartered?
OXOLIFE is headquartered in Barcelona, Barcelona.
When was OXOLIFE founded?
OXOLIFE was founded in 2013.
Build a lead list from companies like OXOLIFE
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.